Adlai Nortye Group Ltd.

Adlai Nortye Group Ltd. について当サイトが保有する最新の四半期

企業自身の 6-K から。

経営陣の発言

“We continue to execute well across our pipeline, with initial clinical data on track for both of our pan-RAS(ON) inhibitor-based assets in 2027,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

Adlai Nortye Group Ltd. の事業内容

Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site. 2) Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells. 4

発表資料の末尾に記載された、企業自身による説明です。